Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Receivables (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Receivables for 2 consecutive years, with $134.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 149.85% to $134.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $134.5 million, a 149.85% increase, with the full-year FY2025 number at $134.5 million, up 149.85% from a year prior.
  • Receivables was $134.5 million for Q4 2025 at Madrigal Pharmaceuticals, up from $113.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $134.5 million in Q4 2025 to a low of $6.9 million in Q2 2024.